H Wiebach1, D Gezer2, T H Brummendorf3, M Crysandt4, S Wilop5. 1. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany. Electronic address: Helen.Wiebach@rwth-aachen.de. 2. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany. Electronic address: dgezer@ukaachen.de. 3. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany. Electronic address: tbrummendorf@ukaachen.de. 4. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany. Electronic address: mcrysandt@ukaachen.de. 5. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; MVZ West GmbH Wuerselen, Hematology - Oncology, Wuerselen, Germany. Electronic address: s.wilop@aachen-onkologie.de.
Abstract
PURPOSE OF THE STUDY: In the past years, high dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT)has more extensively been performed in elderly patients with multiple myeloma (MM). Several studies found a similar survival benefit compared to younger patients. The objective of our retrospective study is to analyse the tolerability of HDT + ASCT in elderly patients. PATIENTS AND METHODS: We compared 26 ASCT performed in MM patients ≥65 years to 127 ASCT in patients <65 years by evaluating treatment-tolerability, length of hospital stay and number of transfusions. RESULTS: There was no significant difference in the duration of hospitalisation (16 days (range 14-47) in the elderly vs. 17 days (range 14-71) days, P = 0.0903), median time of cytopenia (neutrophils<500/μl: 5 days (range 4-24) vs. 6 days (range 3-28) days, P = 0.1091; platelets<30 000/μl: 6 days (range 3-36) vs. 7 days (range 0-53) days, P = 0.274) or incidence of, or degree of complications between the two age-groups. Immediate and day 100 treatment related mortality (TRM) was comparable in both groups (3.85% vs. 1.58%, P = 0.4304). CONCLUSION: our findings support the concept that HDT + ASCT can be safely administered as first-line option for well-selected patients≥65 years.
PURPOSE OF THE STUDY: In the past years, high dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT)has more extensively been performed in elderly patients with multiple myeloma (MM). Several studies found a similar survival benefit compared to younger patients. The objective of our retrospective study is to analyse the tolerability of HDT + ASCT in elderly patients. PATIENTS AND METHODS: We compared 26 ASCT performed in MMpatients ≥65 years to 127 ASCT in patients <65 years by evaluating treatment-tolerability, length of hospital stay and number of transfusions. RESULTS: There was no significant difference in the duration of hospitalisation (16 days (range 14-47) in the elderly vs. 17 days (range 14-71) days, P = 0.0903), median time of cytopenia (neutrophils<500/μl: 5 days (range 4-24) vs. 6 days (range 3-28) days, P = 0.1091; platelets<30 000/μl: 6 days (range 3-36) vs. 7 days (range 0-53) days, P = 0.274) or incidence of, or degree of complications between the two age-groups. Immediate and day 100 treatment related mortality (TRM) was comparable in both groups (3.85% vs. 1.58%, P = 0.4304). CONCLUSION: our findings support the concept that HDT + ASCT can be safely administered as first-line option for well-selected patients≥65 years.
Authors: John A Snowden; Isabel Sánchez-Ortega; Selim Corbacioglu; Grzegorz W Basak; Christian Chabannon; Rafael de la Camara; Harry Dolstra; Rafael F Duarte; Bertram Glass; Raffaella Greco; Arjan C Lankester; Mohamad Mohty; Bénédicte Neven; Régis Peffault de Latour; Paolo Pedrazzoli; Zinaida Peric; Ibrahim Yakoub-Agha; Anna Sureda; Nicolaus Kröger Journal: Bone Marrow Transplant Date: 2022-05-19 Impact factor: 5.174